10月9日，Natera盘中上涨3.05%，报402.71美元/股，成交额1969.63万美元。消息面上，公司多癌早期检测试剂盒获得美国FDA突破性器械认定，叠加此前乳腺癌三期临床启动的积极进展，推动股价在近期获利回吐后重拾升势。
该多癌早筛检测通过分析血液中的游离DNA实现对多种癌症的筛查，突破性器械认定旨在加快产品开发、评估、审评及上市授权流程。此前公司已联合Alliance Foundation Trials启动针对ER阳性/HER2阴性乳腺癌的2000人三期临床，采用Signatera基因组监测指导CDK4/6抑制剂治疗升级，RBC与UBS亦分别将目标价上调至460美元和435美元，反映市场对其MRD及早筛管线的持续信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.